| ORIGINAL ARTICLE |
|
| Ahead of Print |
|
|
Regorafenib and trifluridine/tipiracil in real clinical practice
Nerea García-Beloso, Elena Yaiza Romero-Ventosa, Mónica Gayoso-Rey, Aida López-López, David Robles-Torres, Noemí Martínez-López de Castro, Guadalupe Piñeiro-Corrales
Department of Pharmacy, University Hospital Complex of Vigo, Álvaro Cunqueiro Hospital, Vigo, Pontevedra, Spain
Correspondence Address:
Nerea García-Beloso,
Hospital Pharmacy Service, Álvaro Cunqueiro Hospital, University Hospital Complex of Vigo, 36213 Vigo
Spain
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/jcrt.JCRT_1316_20
|
|
|
Background: Colorectal cancer is the ninth leading cause of death in Spain. The latest therapeutic developments in the advanced stages of this disease are the oral drugs trifluridine/tipiracil and regorafenib.
Objective: Results of clinical trials (CTs) are not in real conditions and therefore, we want to study the effectiveness and the safety profile in the usual clinical practice and compare it with the bibliography.
Materials and Methods: A retrospective and unicentric study was carried out in a health area of 500,000 inhabitants. Patients who started treatment with regorafenib and/or trifluridine/tipiracil were included from the date of marketing until June 2019. Patient-related variables, pathology, effectiveness, and treatment toxicity were collected. The statistical analysis was carried out with the PSPP program.
Results: Fifty-four patients were analyzed. Men accounted for 59.3% of patients. Regorafenib was the treatment for 22.2% of patients and 77.8% received trifluridine/tipiracil. The reason for the drug's suspension was the disease progression in 85.2% of patients. No patient had a full response and 3.2% achieved partial response. The median progression-free survival time in treatments with regorafenib was 2.5 months (95% confidence interval [CI]: 0.0–5.4) and the overall survival time was 3.1 months (95% CI: 0.0–6.7), while in treatments with trifluridine/tipiracil, these data were, respectively, 2.8 (95% CI: 2.5–3.2) and 5.7 months (95% CI: 3.8–7.6). Side effects occurred in 91.7% of patients treated with regorafenib and in 100% of treated with trifluridine/tipiracil. Hematological adverse reactions were, on average, 0.4 ± 0.5/patient with regorafenib and 1.5 ± 0.9 with trifluridine/tipiracil. General (77.8%) and gastrointestinal disorders (50%) were common with both drugs.
Conclusions: The effectiveness results of standard clinical practice are lower than those described in CTs and in the literature. The toxicity profile does reproduce what is described in the bibliography.
|
|
|
|
|
|
|
Search Pubmed for